Why did xfor just spike upward

The stock price of XFOR has experienced an increase of 28.2% on November 14. The recent upward spike in XFOR's stock price can be attributed to several positive developments:

|Ticker|Name|Date|Percentage Change|code|market_code|
|---|---|---|---|---|---|
|XFOR.O|X4 Pharmaceuticals|20241108|0.1297|XFOR|186|

1. **Positive Clinical Trial Results**: X4 Pharmaceuticals has reported positive results from their completed Phase 2 study of mavorixafor in chronic neutropenia. These results have bolstered confidence in the ongoing pivotal Phase 3 4WARD trial.
2. **FDA Approval and Product Launch**: The company has received FDA approval for their first product, Maverick, for the treatment of WHIM syndrome. The launch of XOLREMDI® (mavorixafor) is underway, and the company is seeing increased awareness of WHIM syndrome among potential prescribers.
3. **Financial Resilience**: X4 Pharmaceuticals has a strong financial position with cash and equivalents of almost $136 million, providing a financial runway into late 2025. This financial resilience may have contributed to the market's positive sentiment.

These positive developments have likely contributed to the recent upward movement in XFOR's stock price.

|Ticker|Name|Date|Post-Market Percentage Change|Pre-Market Percentage Change|code|market_code|
|---|---|---|---|---|---|---|
|XFOR.O|X4 Pharmaceuticals|20241114|10.16949152542373|14.929679047962491|XFOR|186|